Index of drugs

No ovulation (including polycystic PCOS ovary syndrome) in women who have not responded to treatment with clomiphene citrate. Multi-ventricular stimulation in patients undergoing reproduction support, such as fertilizationin vitro, gamete transfer to the fallopian tube and transfer of zygote to the fallopian tube.

1 vial contains 75 IU urofolitropiny.

Follicle-stimulating hormone (FSH) obtained from human menopausal gonadotropin (HMG). It stimulates the development and maturation of Graaf's follicles. After intramuscular or subcutaneous administration, bioavailability is about 70%. T_0,5 is 30-40 hours.

Hypersensitivity to the components of the preparation. Ovarian enlargement or ovarian cysts not associated with polycystic ovary syndrome. Bleeding from the genital tract of unknown cause. Cancers of the ovaries, uterus and breast. Neoplasms of the hypothalamus or pituitary gland. The preparation should not be used in patients if the appropriate response to treatment can not be achieved due to: primary ovarian failure, genital malformation or uterine tumors that prevent the normal course of pregnancy.

Before starting treatment, exclude hypothyroidism, adrenal insufficiency, hyperprolactinemia and pituitary or hypothalamic tumors. Particularly cautiously use in patients with hypersensitivity to gonadotropin (the first injection should be made by the physician in conditions that enable resuscitation). Due to the increased risk of venous or arterial thromboembolism, the risks and benefits of extracorporeal fertilization program should be considered in patients with risk factors for a blood clot in a family history or history of embolism, significant obesity (WMC> 30kg / m²).

Do not use during pregnancy and breast-feeding.

Common: headache, constipation, abdominal distension, ovarian hyperstimulation syndrome, pain. Uncommon: hyperthyroidism, mood disorders, lethargy, dizziness, shortness of breath, nosebleeds, nausea, abdominal pain, indigestion, erythema, pruritus, cystitis, hypertrophy of the breasts, breast pain, hot flushes, fatigue, prolonged bleeding time. Rarely: reactions at the injection site (pain, redness and hematoma), arterial thrombus with congestion. A slightly higher prevalence of ectopic pregnancy, multiple pregnancy and miscarriage was observed. The incidence of congenital defects after using reproduction technology may be slightly higher than after natural fertilization.

Intramuscularly or subcutaneously. Treatment with the preparation should be carried out under the supervision of a physician experienced in the treatment of infertility.No ovulation (including PCOS). The goal of treatment is to develop a single, mature Graafian follicle from which the oocyte will be released after hCG administration. Treatment should be tailored to the patient's individual response, as assessed by ultrasound and / or estradiol. In menstruating patients, treatment should begin within the first 7 days of the cycle. The usual starting dose is 75-450 IU. FSH daily, if necessary, the dose can be increased by 37.5 IU. (up to 75 IU) every 7-14 days, the preparation can be administered once a day. The daily dose should be maintained until the conditions for ovulation are reached, usually 7-14 days of treatment. Subsequently, administration of the preparation should be discontinued and ovulation may be induced by administration of hCG. If the number of corresponding follicles is too high or the estradiol concentration increases too quickly, eg twice a day for 2-3 days, the daily dose of the preparation should be reduced. In the case of a larger number of follicles with a diameter of 14 mm in the preovulatory phase increases the risk of multiple pregnancy. The patient should use mechanical methods of contraception or avoid relationships until the Next menstrual period. Treatment should be restarted in the next cycle from the lower dose. The maximum daily dose of FSH is usually 225 IU. If the patient does not respond adequately after 4 weeks of treatment, stop treatment and start again in the next cycle with a higher starting dose.After receiving a response, 24-48 hours after the last FSH injection, you should inject 5,000-10,000 IU at a time. hCG. The patient should have the ratio on the day of hCG injection and the next day. Alternatively, intrauterine insemination can be performed.Multi-ventricular stimulation in patients undergoing reproduction support. The most frequent administration of the preparation begins about 2 weeks after the beginning of administration of gonadotrophin releasing hormone (GnRH), both drugs are administered simultaneously until a properly developed follicle, eg after 2 weeks of GnRH administration, should be administered 150-225 IU. FSH for 7 days, then the FSH dose should be adjusted to the patient's response to treatment). Alternative procedure: 150-225 IU FSH daily, starting from the 2nd or 3rd day of the cycle. Treatment should be continued until developed vesicles (assessment based on estradiol and / or USG). The dose should be adjusted to the patient's response (usually the dose is not higher than 450 IU per day). Appropriate follicular development usually takes place around the 10th day of treatment (from the 5th to the 20th day). After an optimal response to treatment, 24-48 hours after the last FSH injection, you should inject 5,000-10,000 IU at a time. hCG. Ovulation occurs 34-25 h after hCG administration.